注射用丹参多酚酸盐的药学综合评价

doi:10.11669/cpj.2021.05.014

PDF(1296 KB)

中国药学杂志 ›› 2021, Vol. 56 ›› Issue (5) : 422-428. DOI: 10.11669/cpj.2021.05.014

论著

注射用丹参多酚酸盐的药学综合评价

韩晟¹, 赵熙子¹, 史录文^1*, 林丽开², 李大魁³, 陈凯先⁴, 宣利江⁴, 马传江⁵, 马海英⁶, 方唯一⁷, 王丽霞⁸, 文爱东⁹, 付秀娟¹⁰, 左燕¹¹, 刘小玲¹², 刘向红¹³, 刘国强¹⁴, 朱珠³, 陈万生¹⁵, 陈维红¹⁶, 吴方建¹⁷, 吴玉波¹⁸, 吴晖¹⁹, 张伟²⁰, 张毕奎²¹, 林慧²², 周国华²³, 欧阳荣²⁴, 胡元会⁸, 姜明燕²⁵, 赵春景²⁶, 贾乐川²⁷, 晋月萍²⁸, 唐洪梅²⁹, 曹俊岭³⁰, 梁春¹⁵, 商洪才³¹, 董占军³², 董吁钢³³, 翟所迪³⁴

作者信息 +

1.北京大学医药管理国际研究中心, 北京 100191;
2.武汉大学中南医院武汉大学医院管理研究所, 武汉 430071;
3.北京协和医院, 北京 100730;
4.中国科学院上海药物研究所, 上海 201203;
5.山东中医药大学附属医院, 济南 250014;
6.中国医科大学附属第四医院, 沈阳 110000;
7.复旦大学附属华东医院, 上海 200030;
8.中国中医科学院广安门医院, 北京 100053;
9.中国人民解放军空军军医大学第一附属医院, 西安 710032;
10.吉林大学第二医院, 长春 130041;
11.陕西省人民医院, 西安 710068;
12.内蒙古自治区人民医院, 呼和浩特 010017;
13.山东大学齐鲁医院, 济南 250012;
14.河北医科大学第三医院, 石家庄 050051;
15.上海长征医院, 上海 200003;
16.山西白求恩医院(山西医学科学院), 太原 030032;
17.长江航运总医院, 武汉 430015;
18.哈尔滨医科大学附属第四医院, 哈尔滨 150001;
19.昆明医科大学第一附属医院, 昆明 650032;
20.河南省人民医院, 郑州 450003;
21.中南大学湘雅二医院, 长沙 410011;
22.海南省药学会, 海口 570102;
23.南京大学医学院附属金陵医院, 南京 210000;
24.湖南中医药大学第一附属医院, 长沙 410007;
25.中国医科大学附属第一医院, 沈阳 110001;
26.重庆医科大学附属第二医院, 重庆 400010;
27.宁夏医科大学总医院, 银川 750004;
28.山西医科大学第一医院, 太原 030001;
29.广州中医药大学第一附属医院, 广州 510405;
30.北京中医药大学东方医院, 北京 100078;
31.北京中医药大学东直门医院, 北京 100007;
32.河北省人民医院, 石家庄 050051;
33.中山大学附属第一医院, 广州 510080;
34.北京大学第三医院, 北京 100191

作者简介:

韩晟,男,博士,研究方向:药物经济学,药品综合评价; 赵熙子,女,硕士,研究方向:药品综合评价。韩晟与赵熙子为共同第一作者

折叠

Comprehensive Pharmacological Evaluation of Salvia Miltiorrhiza Depside Salts for Injection

HAN Sheng¹, ZHAO Xi-zi¹, SHI Lu-wen^1*, LIN Li-kai², LI Da-kui³, CHEN Kai-xian⁴, XUAN Li-jiang⁴, MA Chuan-jiang⁵, MA Hai-ying⁶, FANG Wei-yi⁷, WANG Li-xia⁸, WEN Ai-dong⁹, FU Xiu-juan¹⁰, ZUO Yan¹¹, LIU Xiao-ling¹², LIU Xiang-hong¹³, LIU Guo-qiang¹⁴, ZHU Zhu³, CHEN Wan-sheng¹⁵, CHEN Wei-hong¹⁶, WU Fang-jian¹⁷, WU Yu-bo¹⁸, WU Hui¹⁹, ZHANG Wei²⁰, ZHANG Bi-kui²¹, LIN Hui²², ZHOU Guo-hua²³, OUYANG Rong²⁴, HU Yuan-hui⁸, JIANG Ming-yan²⁵, ZHAO Chun-jing²⁶, JIA Le-chuan²⁷, JIN Yue-ping²⁸, TANG Hong-mei²⁹, CAO Jun-ling³⁰, LIANG Chun¹⁵, SHANG Hong-cai³¹, DONG Zhan-jun³², DONG Yu-gang³³, ZHAI Suo-di³⁴

Author information +

1. Peking University International Research Center for Medical Administration, Beijing 100191, China;
2. Wuhan University Central South Hospital, Wuhan University Hospital Management Institute, Wuhan 430071, China;
3. Peking Union Medical College Hospital, Beijing 100730, China;
4. Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China;
5. Shandong Traditional Chinese Medicine University Hospital, Jinan 250014, China;
6. The Fourth Affiliated Hospital of China Medical University, Shenyang 110000, China;
7. East China Hospital Affiliated to Fudan University, Shanghai 200030, China;
8. Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China;
9. PLA Air Force Military Surgeon The First Affiliated Hospital of University, Xi'an 710032, China;
10. The Second Hospital of Jilin University, Changchun 130041, China;
11. Shaanxi Provincial People's Hospital, Xi'an 710068, China;
12. Inner Mongolia Autonomous Region People's Hospital, Hohhot 010017, China;
13. Qilu Hospital of Shandong University, Jinan 250012, China;
14. The Third Hospital of Hebei Medical University, Shijiazhuang 050051, China;
15. Shanghai Changzheng Hospital, Shanghai 200003, China;
16. Shanxi Bethune Hospital (Shanxi Academy of Medical Sciences), Taiyuan 030032, China;
17. Yangtze River Shipping General Hospital, Wuhan 430015, China;
18. The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, China;
19. The First Affiliated Hospital of Kunming Medical University, Kunming 650032, China;
20. Henan Provincial People's Hospital, Zhengzhou 450003, China;
21. The Second Xiangya Hospital of Central South University, Changsha 410011, China;
22. Hainan Province Pharmaceutical Association, Haikou 570102, China;
23. Jinling Hospital Affiliated to Nanjing University School of Medicine, Nanjing 210000, China;
24. The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Changsha 410007, China;
25. The First Affiliated Hospital of China Medical University, Shenyang 110001, China;
26. Chongqing Medical University, The Second Affiliated Hospital of University, Chongqing 400010, China;
27. The General Hospital of Ningxia Medical University, Yinchuan 750004, China;
28. The First Hospital of Shanxi Medical University, Taiyuan 030001, China;
29. The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China;
30. Beijing Zhong Eastern Hospital of Medical University, Beijing 100078, China;
31. Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100007, China;
32. Hebei Provincial People's Hospital, Shijiazhuang 050051, China;
33. The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China;
34. Peking University Third Hospital, Beijing 100191, China

Collapse

文章历史 +

摘要

目的以注射用丹参多酚酸盐为例,探索中药注射剂的综合评价方法,为今后相关工作的开展和完善提供参考。方法通过文献检索和获取相关文献资料,从药学特性、质量等方面对注射用丹参多酚酸盐进行药学综合评价。结果在有效成分和药物作用机制方面,丹参多酚酸盐已经进行了大量的基础研究。质量方面的文献证据也较为丰富。结论注射用丹参多酚酸盐在药学特性方面研究探索面非常广,相关基础研究还有待进一步探索。

Abstract

OBJECTIVE To explore the comprehensive evaluation method of traditional Chinese medicine injection, and to provide reference for the development and improvement of related work in the future. Taking Salvia Miltiorrhiza depside salts for injection as an example. METHODS Through literature and relevant literature materials, comprehensive pharmacological evaluation of Salvia Miltiorrhiza depside salts for injection was carried out in terms of pharmaceutical properties and quality. RESULTS In terms of active ingredients and drug mechanism of action, Salvia Miltiorrhiza depside salts has undergone a lot of basic research. The literature on quality is also abundant. CONCLUSION The research and exploration of Salvia Miltiorrhiza depside salts for injection has a wide range of pharmaceutical properties, and related basic research needs to be further explored.

导出引用

韩晟, 赵熙子, 史录文, 林丽开, 李大魁, 陈凯先, 宣利江, 马传江, 马海英, 方唯一, 王丽霞, 文爱东, 付秀娟, 左燕, 刘小玲, 刘向红, 刘国强, 朱珠, 陈万生, 陈维红, 吴方建, 吴玉波, 吴晖, 张伟, 张毕奎, 林慧, 周国华, 欧阳荣, 胡元会, 姜明燕, 赵春景, 贾乐川, 晋月萍, 唐洪梅, 曹俊岭, 梁春, 商洪才, 董占军, 董吁钢, 翟所迪. 注射用丹参多酚酸盐的药学综合评价[J]. 中国药学杂志, 2021, 56(5): 422-428 https://doi.org/10.11669/cpj.2021.05.014

HAN Sheng, ZHAO Xi-zi, SHI Lu-wen, LIN Li-kai, LI Da-kui, CHEN Kai-xian, XUAN Li-jiang, MA Chuan-jiang, MA Hai-ying, FANG Wei-yi, WANG Li-xia, WEN Ai-dong, FU Xiu-juan, ZUO Yan, LIU Xiao-ling, LIU Xiang-hong, LIU Guo-qiang, ZHU Zhu, CHEN Wan-sheng, CHEN Wei-hong, WU Fang-jian, WU Yu-bo, WU Hui, ZHANG Wei, ZHANG Bi-kui, LIN Hui, ZHOU Guo-hua, OUYANG Rong, HU Yuan-hui, JIANG Ming-yan, ZHAO Chun-jing, JIA Le-chuan, JIN Yue-ping, TANG Hong-mei, CAO Jun-ling, LIANG Chun, SHANG Hong-cai, DONG Zhan-jun, DONG Yu-gang, ZHAI Suo-di. Comprehensive Pharmacological Evaluation of Salvia Miltiorrhiza Depside Salts for Injection[J]. Chinese Pharmaceutical Journal, 2021, 56(5): 422-428 https://doi.org/10.11669/cpj.2021.05.014

中图分类号： R95

参考文献

[1] Ch.P(2020). VolⅠ(中国药典2020年版.一部)[S]. 2020:1306.
[2] Ch.P(2020). VolⅠ(中国药典2020年版.一部)[S]. 2020:1311.
[3] DONG P X, HU H, GUAN X D, et al. Cost-consequence analysis of salvianolate injection for the treatment of coronary heart disease[J]. Chin Med, 2018, 13(10):28 .
[4] ZHANG J H, SUN X. Evidence-based Chinese Medicine(循证中医药学)[M]. Shanghai: Shanghai Science and Technology Press, 2018: 184-186.
[5] SHI L W, ZHU W T, WU J, et al. Technical Manual of Pharmacoeconomic Evaluation of Chinese Patent Medicine(中成药药物经济学评价手册)[M]. Beijing:Peking Union Medical College Press, 2019:1-2.
[6] PROJECT TEAM OF GUIDELINES FOR COMPREHENSIVE EVALUATION OF CHINESE DRUGS. Reference Outline of Chinese Guidelines for Comprehensive Evaluation of Drugs (Second Edition)[J]. Pharm Eval(药品评价), 2015,12(8):6-14.
[7] Group of Guideline for Comprehensive Evaluation of Medicine in China. Guideline for comprehensive evaluation of medicine in China[J]. Drug Eval, 2011, 8(18): 6-22.
[8] WU W Y, WANG Y P. Pharmacological actions and therapeutic applications of salvia miltiorrhizadepside salt and its active components[J]. Acta Pharm Sin(药学学报), 2012, 47(9):1119-1130.
[9] LIU Y L, ZHOU X Y, XUAN L J. Magnesium lithospermate B ameliorates microcirculation perfusion in rats by promoting vascular NO production via activating the PI3K/AKT pathway[J]. Acta Pharm Sin(药学学报), 2019,54(3):1-9.
[10] CHANG C Z, WU S C, KWAN A L, et al. Magnesium lithospermate B alleviates the production of endothelin-1 through an NO-dependent mechanism and reduces experimental vasospasm in rats[J]. Acta Neurochir, 2011, 153(11):2211-2217.
[11] ZHANG Y. Effect of salvia miltiorrhiza polyphenolate on serum inflammatory factors in acute coronary syndrome and clinical observation[J]. Foreign Med(Antibiotics), 2014, 35(5):230-232.
[12] ZHANG H, ZHANG Y, YANG R, et al. Related research on the effect of salvia miltiorrhiza polyphenolate on inflammatory factors in patients with acute coronary syndrome[J]. Chin J Integr Tradit Chin Western Med(中国中西医结合杂志), 2013, 33(5):598-601.
[13] XIONG T, WU X J, WANG Y P. Salvia miltiorrhiza polyphenolate inhibits oxidative modification of low density lipoprotein[J]. Pharm Clin Chin Mater Med, 2004, (4):7-10.
[14] LI B, LI X, MA X L, et al. Study on the protective effect and mechanism of salvia miltiorrhiza polyphenolate on isolated rat heart ischemia-reperfusion injury[J]. China Emerg Tradit Chin Med(中国中医急症), 2018, 27(5):854-857.
[15] SHEN J L, ZHU K J, LI Z N, et al. Protective effects of salvia miltiorrhiza polyphenolate pretreatment on myocardial ischemia-reperfusion injury in rats[J]. J Clin Cardiovascular Dis, 2012, 28(9): 707-710.
[16] XU J P, SUN L S, WU H Y, et al. Protective effects of salvianolic acid B on myocardial ischemia/reperfusion injury in rats[J]. Chin Pharm J(中国药学杂志), 2003,38(8):595-597.
[17] YAN P, LUO X P, SHI H M, et al. Clinical study on the effect of salvia miltiorrhiza polyphenolate on platelet function[J]. Mod J Int Tradit Chin Western Med(现代中西医结合杂志), 2005, 14(16):2092-2094.
[18] WANG W, WANG Y P, SUN W K, et al. Effects of magnesium lithospermate B on aggregation and 5-HT release in rabbit washed platelets[J]. Acta Pharmacol Sin, 2000, 21(9):859-863.
[19] CHEN Y H, DU G H, ZHANG J T. Salvianolic acid B protects brain against injuries caused by ischemia-reperfusion in rats[J]. Acta Pharmacol Sin, 2000, 21(9):463-466.
[20] TZEN J T, JINN T R, CHEN Y C, et al. Magnesium lithospermate B possesses inhibitory activity on Na⁺, K⁺-ATPase and neuroprotective effects against ischemic stroke[J]. Acta Pharmacol Sin, 2007,28(5):609-615.
[21] YAO G, XU L, WU X, et al. Preventive effects of salvianolic acid B on transforming growth factor-beta1-induced epithelial-to-mesenchymal transition of human kidney cells[J]. Biol Pharm Bull, 2009, 32(3):882-886.
[22] PAN R H, XIE F Y, CHEN H M, et al. Salvianolic acid B reverses the epithelial-to-mesenchymal transition of HK-2 cells that is induced by transforming growth factor-beta[J]. Arch Pharm Res, 2011, 34(3):477-483.
[23] WANG Q L, TAO Y Y, YUAN J L, et al. Salvianolic acid B prevents epithelial-to-mesenchymal transition through the TGF-beta1 signal transduction pathway in vivo and in vitro[J]. BMC Cell Biol, 2010,11(11):31.
[24] LIN Y L, WU C H, LUO M H, et al. In vitro protective effects of salvianolic acid B on primary hepatocytes and hepatic stellate cells[J]. J Ethnopharmacol, 2006, 105(1-2):215-222.
[25] PAIK Y H, YOON Y J, LEE H C, et al. Antifibrotic effects of magnesium lithospermate B on hepatic stellate cells and thioacetamide-induced cirrhotic rats[J]. Exp Mol Med, 2011,43(6):341-349.
[26] TSAI M K, LIN Y L, HUANG Y T. Effects of salvianolic acids on oxidative stress and hepatic fibrosis in rats[J]. Toxicol Appl Pharmacol, 2010, 242(2): 55-164.
[27] JIANG F, MAO Y, LIU H, et al. Magnesium lithospermate B protects neurons against amyloid beta (1-42)-induced neurotoxicity through the NF-kappaB pathway[J]. Neurochem Res, 2015, 40(9):1954-1965.
[28] MU D G, JIN F G, CHU D L, et al. Experimental study of salvia miltiorrhiza polyphenolate on the prevention and treatment of acute lung injury[J]. J Pract Med(实用医学杂志), 2010, 26(15):2717-2719.
[29] YANG D H, YE Z Y, HE X J, et al. Salvia miltiorrhiza polyphenolate improves intestinal mucosal barrier function in rats with experimental liver cirrhosis[J]. Chin J Clin Pharmacol Therapeut(中国临床药理学杂志), 2010, 15(7):758-763.
[30] JIANG X Y, RONG L, XIA T T, et al. Salvia miltiorrhiza polyphenolic acid modulates NOD-like receptor family including pyrin domain protein 3 inflammasome activity in the treatment of murine colitis[J]. Chin J Digest(中华消化杂志), 2017, 37 (9):619-623.
[31] LIU G T, CHEN Q, JIN L M, et al. Salvia miltiorrhiza polyphenolate combined with povidone iodine to prevent postoperative intestinal adhesions in rats[J]. Zhejiang J Integr Tradit Chin Western Med(浙江中西医结合杂志), 2015, 25(6):538-541.
[32] ZHANG B, XIE Q P, CHEN S. Experimental study of salvia miltiorrhiza polyphenolate in preventing vascular crisis of DIEP flap in miniature pigs[J]. Zhejiang Med(浙江医学), 2014, 36(6):494-496.
[33] SONG S H, GUO W Y, FU Z R, et al. Donor liver salvia polyphenolate pretreatment reduces biliary tract injury after liver transplantation in recipient rats[J]. J Second Mil Med Univ(第二军医大学学报), 2010, 31(2):136-139.
[34] LI X, YU C, LU Y, et al. Pharmacokinetics, tissue distribution, metabolism, and excretion of depside salts from Salvia miltiorrhiza in rats[J]. Drug Metab Dispos, 2007, 35(2):234-239.
[35] LI X, YU C, SUN W, et al. Simultaneous determination of magnesium lithospermate B, rosmarinic acid, and lithospermic acid in beagle dog serum by liquid chromatography/tandem massspectrometry[J]. Rapid Commun Mass Spectrom, 2004, 18(23):2878-2882.
[36] JIA J Y, LU Y L, LI X C, et al. Pharmacokinetics of depside salts from Salvia miltiorrhiza in healthy Chinese volunteers: a randomized, open-label, single-dose study[J]. Curr Ther Res, 2010, 71(4):260-271.
[37] GAO R, ZHANG Y, WANG S C. Pharmacokinetics and pharmacodynamics of salvianolic acid in healthy volunteers[J]. Chin J Clin Pharm Ther(中国临床药理学与治疗学杂志), 2004, 9(11):1209-1212.
[38] ZHANG Y, GAO R, et al. Pharmacokinetics of salvianolic acid B in patients with coronary heart disease and blood stasis syndrome[J]. Pharm Clin Chin Mater Med(中药药理与临床), 2010, 26(6):22-24.
[39] LU S W, GUO J Y, ZHU Y L. Analysis of the use of Salvia miltiorrhiza polyphenolate for injection in tertiary first-class hospitals[J]. China Med Herald(中国医药导报), 2014, 11(36):96-99.
[40] ZHOU X, GUO D H, ZHU M, et al. Observation and study on the clinical application of Salvia Miltiorrhiza Polyphenolate for injection in diabetic patients[J]. Chin J Drug Appl Monitor(中国药物应用与监测), 2014, 11(3):142-145.
[41] WANG Z Z. Study on the stability of Salvia Miltiorrhiza Polyphenolate for injection and 12 solvents[J]. Chin Pharm(中国药师), 2009, 12(6):774-776.
[42] GAO Y C, SU L L, ZHAO Z G. A case report of allergic reaction caused by compound Danshen injection[J]. Chin Pharm J(中国药学杂志), 2007,42(18):1439.
[43] GONG C Y, SHEN G Q, CHEN L. Compatible application of compound Danshen injection with fleroxacin glucose injection[J]. Jiangsu Pharm Clin Res(江苏药学与临床研究), 2004,(S1):27-28.
[44] WANG Z Y, TONG A, TANG H. Tashinone ⅡA sodium sulfonate and potassium chloride exist compatibility taboo[J]. Acta Nur Care(护理学报), 2009, 16(2):73.
[45] LIU W, DU X F, ZHANG M L, et al. Study on the stability of phenolic acids in the compatibility of Danhong injection and vitamin B6 injection[J]. J Hebei Med Univ(河北医科大学学报), 2009, 30(6):582-584.
[46] ZHANG M L, WANG L Y, ZHANG J R, et al. Study on the stability of the compatibility of Danhong injection with several common clinical drugs[J]. Hebei Med(河北医药), 2008(9):1422-1423.
[47] CAO J Y. There are contraindications in the compatibility of tanshinone ⅡA sodium sulfonate and potassium chloride in the same syringe[J]. Anhui Med(安徽医药), 2010, 14(5):595.
[48] LIN P. Intervention of botanical drugs for risk factors of cardiovascular and cerebrovascular diseases and changes in compatibility[J]. Pract J Cardio-Cerebral Pneumal Vascul Dis(实用心脑肺血管病杂志), 2009, 17(10):897-898.
[49] YU M M. Salvia Miltiorrhiza Polyphenolate for injection and amoxicillin sodium for injection and flucloxacillin sodium for injection have contraindications[J]. Chin J Mod Nur(中华现代护理杂志), 2011, 17(22):2712-2712.
[50] CHEN Y, LIU Q Q, XIAO Y T. Study on the stability of compatibility of cefmetazole sodium for injection with two drugs[J]. J China Pharm(中国药房), 2012, 23(18):1679-1681.
[51] ZHOU X H. There are contraindications between Salvia miltiorrhiza polyphenolate for injection and Ciprofloxacin lactate and sodium chloride injection[J]. Chin J Pract Nurs(中国实用护理杂志), 2013,29(15):14.
[52] LUO L X, LIU D P, XIA F Q. Salvia Miltiorrhiza Polyphenolate for injection and potassium magnesium aspartate injection have contraindications[J]. Med Nat Defense Southwest China(西南国防医药), 2011, 21(12):1362.
[53] REN X, XIE N, XU X Y, et al. Study on the stability of compatibility of Salvia miltiorrhiza polyphenolate for injection with 21 common clinical drugs[J]. China Pharm(中国药业), 2012, 21(2):22-25.
[54] LI S, LIANG L, LIU J, et al. Salvia Miltiorrhiza Polyphenolate for injection and fasudil hydrochloride injection have compatibility contraindications[J]. Chin J Lung Dis(Elec Ed)(中华肺部疾病(电子版)), 2013, 6(5): 415.
[55] ZHANG H L. There are contraindications between Salvia Miltiorrhiza Polyphenolate for injection and Cinepazide maleate injection[J]. North China Nat Defense Med(华北国防医药), 2011, 22(4):138.
[56] DENG L, ZHANG J H, LIU X. There is a contraindication between Vinpocetine injection and Salvia Miltiorrhiza Polyphenolate for injection[J]. J Clin Rat Use(临床药理学用药杂志), 2013, 6(26):90.
[57] REN X, et al. Study on the stability of compatibility of Salvia Miltiorrhiza Polyphenolate for injection with 21 common clinical drugs[J]. China Pharm(中国药业), 2012, 21(2):22-25.
[58] LU Y L. Omeprazole sodium for injection and Salvia Miltiorrhiza Polyphenolate for injection have contraindications[J]. Chin J Mod Nur(中国现代护理杂志), 2011, 17(9):1074.
[59] WANG Y X. There is a contraindication between Salvia Miltiorrhiza Polyphenolate for injection and Lansoprazole for injection[J]. Chin J Misdiag(中国误诊学杂志), 2011, 11(15):3728.
[60] LU Z X, ZHONG Y X, BAN F, et al. Pantoprazole sodium for injection and Salvia Miltiorrhiza Polyphenolate for injection have contraindications[J]. Qilu J Nur(齐鲁护理杂志), 2011, 17(12):20.
[61] LI Y Z, WEI F L. SSalvia Miltiorrhiza Polyphenolate for injection and ondansetron hydrochloride have contraindications[J]. J Clin Rat Use(临床合理用药), 2012, (3):70.
[62] HUANG L L. There is a contraindication between Salvia Miltiorrhiza Polyphenolate for injection and papaverine hydrochloride[J]. Contem Nur(当代护士), 2016, (3):117.
[63] LIN X M. Study on the compatibility and stability of Danshen injection[J]. Chin J Drug Eval(中国药学评价), 2016, 33(1):20-23.
[64] MO Y Y. The observation experience of the compatibility of compound Danshen injection with three drugs[J]. J Guilin Med College(桂林医学院学报), 1996,(S1):97-98.
[65] HUANG T Y, SHI S Y, ZHOU L Q. Reevaluation of the stability of Salvia Miltiorrhiza Polyphenolate for injection[J]. Chin J Biochem Pharm(中国生化药物杂志), 2016, 3(36):157-162.

PDF(1296 KB)

305

Accesses

Citation

Detail

段落导航

摘要
Abstract
关键词
Key words
引用本文
参考文献

收稿日期	出版日期
2020-08-27	2021-03-08
发布日期
2021-04-20

选择文件类型/文献管理软件名称

选择包含的内容

摘要

Abstract

关键词

Key words

引用本文

{{custom_sec.title}}

{{custom_sec.title}}

参考文献

{{custom_fnGroup.title_cn}}

脚注

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

摘要

Abstract

关键词

Key words

引用本文

{{custom_sec.title}}

{{custom_sec.title}}

参考文献

{{custom_fnGroup.title_cn}}

脚注